GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » MedAvail Holdings Inc (OTCPK:MDVLQ) » Definitions » EBITDA

MedAvail Holdings (MedAvail Holdings) EBITDA : $-35.26 Mil (TTM As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is MedAvail Holdings EBITDA?

MedAvail Holdings's EBITDA for the three months ended in Jun. 2023 was $-4.92 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-35.26 Mil.

During the past 3 years, the average EBITDA Growth Rate was -29.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 4 years, the highest 3-Year average EBITDA Growth Rate of MedAvail Holdings was -29.70% per year. The lowest was -29.70% per year. And the median was -29.70% per year.

MedAvail Holdings's EBITDA per Share for the three months ended in Jun. 2023 was $-2.74. Its EBITDA per share for the trailing twelve months (TTM) ended in Jun. 2023 was $-21.65.

During the past 3 years, the average EBITDA per Share Growth Rate was -1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 4 years, the highest 3-Year average EBITDA per Share Growth Rate of MedAvail Holdings was -1.60% per year. The lowest was -1.60% per year. And the median was -1.60% per year.


MedAvail Holdings EBITDA Historical Data

The historical data trend for MedAvail Holdings's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedAvail Holdings EBITDA Chart

MedAvail Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22
EBITDA
-19.16 -23.76 -40.65 -41.77

MedAvail Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.47 -9.71 -9.12 -11.51 -4.92

Competitive Comparison of MedAvail Holdings's EBITDA

For the Pharmaceutical Retailers subindustry, MedAvail Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedAvail Holdings's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MedAvail Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MedAvail Holdings's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

MedAvail Holdings's EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

MedAvail Holdings's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2022, MedAvail Holdings's EBITDA was $-41.77 Mil.

MedAvail Holdings's EBITDA for the quarter that ended in Jun. 2023 is calculated as

MedAvail Holdings's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Jun. 2023, MedAvail Holdings's EBITDA was $-4.92 Mil.

EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

MedAvail Holdings  (OTCPK:MDVLQ) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


MedAvail Holdings EBITDA Related Terms

Thank you for viewing the detailed overview of MedAvail Holdings's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


MedAvail Holdings (MedAvail Holdings) Business Description

Traded in Other Exchanges
N/A
Address
4720 East Cotton Gin Loop, Suite 220, Phoenix, AZ, USA, 85040
MedAvail Holdings Inc is a telehealth-enabled pharmacy technology company. It operates in two segments: Retail Pharmacy Services and Pharmacy Technology. It generates the majority of revenue from the Retail Pharmacy Services segment, which is into operating SpotRx, a full-service retail pharmacy utilizing MedAvail's automated pharmacy technology, primarily servicing Medicare patients in the United States. The Pharmacy Technology segment develops and commercializes the MedCenter for direct sale or lease to third-party customers.
Executives
Ramona Seabaugh officer: Chief Financial Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Michael R Kramer director 3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Paul D Johnson director 440 N BARRANCA AVE #3550, COVINA CA 91723
Glen D. Stettin director C/O EXPRESS SCRIPTS HOLDING COMPANY, ONE EXPRESS WAY, ST. LOUIS MO 63121
Mark Edward Doerr director, officer: Chief Executive Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Abg Wtt-medavail Ltd 10 percent owner 15 QUEENS ROAD CENTRAL, UNIT 3002-3004, 30TH FLOOR, GLOUCESTER TWR, THE LANDMARK, HONG KONG F4 0000000000
Redco Ii Master Fund, L.p. director, 10 percent owner ONE LETTERMAN DRIVE, BLDG D, STE D3-300, SAN FRANCISCO CA 94129
Alyeska Fund Gp, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investment Group, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investments, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Anand Parekh 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Master Fund, L.p. 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investment Group, L.p. 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Steven Hess officer: Executive Vice President C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Edwin Kilroy director, officer: Chief Executive Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4

MedAvail Holdings (MedAvail Holdings) Headlines